Skip to main content
. 2017 Oct 4;8(51):88904–88917. doi: 10.18632/oncotarget.21492

Figure 6. Plasma galectin-9 levels were associated with shorter OS times in MDS patients.

Figure 6

(A) The high galectin-9 group of MDS patients (>10 ng/ml, solid line) had shorter OS compared with the low group (≤10 ng/ml, dotted line). (B) In MDS patients with RA/RARS, the high galectin-9 group had shorter OS in comparison with the low group.